Optimal Management of Heart Failure with Hypertension and Diabetes

Introduction to Guideline-Directed Medical Therapy

The American College of Cardiology recommends SGLT2 inhibitors like dapagliflozin as guideline-directed medical therapy (GDMT) for heart failure, added to beta-blockers, ACE inhibitors/ARBs/ARNIs, and aldosterone antagonists 1
SGLT2 inhibitors provide mortality benefit and reduce heart failure hospitalizations independent of blood pressure or glucose effects 1

The American College of Cardiology suggests that ramipril reduces cardiovascular death by 37%, MI by 22%, and stroke by 33% in diabetic patients with cardiovascular risk factors, according to the American Heart Association guidelines 2
Ramipril reduces diabetic nephropathy, need for dialysis, and retinopathy requiring laser therapy in diabetic patients, as recommended by the American Diabetes Association 2
ACE inhibitors should be first-line therapy for patients with stable CAD and hypertension, targeting BP <130/80 mmHg, as per the American College of Cardiology guidelines 2

The American College of Cardiology recommends adding ramipril to the existing Farxiga regimen rather than substituting one for the other, as both medications provide distinct, complementary cardiovascular and mortality benefits in heart failure with reduced ejection fraction (HFrEF) 1
Both medications work through different mechanisms and provide additive cardiovascular protection, according to the European Society of Cardiology guidelines 1
In clinical trials, SGLT2 inhibitors showed consistent benefit even in patients already receiving ACE inhibitors or ARNIs, as reported by the American Heart Association 1

The American College of Cardiology suggests monitoring blood pressure, with a target <130/80 mmHg in diabetic patients with CAD, as recommended by the American Heart Association 2
Renal function, including creatinine and eGFR, should be monitored at baseline, 1-2 weeks after initiation, and with each dose increase of ramipril, according to the National Kidney Foundation guidelines 1
Potassium levels should be monitored due to the risk of hyperkalemia, especially in diabetic patients with renal impairment, as per the American College of Cardiology guidelines 1
Weight and volume status should be monitored, with adjustments to diuretics as needed to maintain euvolemia, as recommended by the European Society of Cardiology 1